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Acommonfeaturesharedbetweenseveralhumancancer-associated
viruses, such as Epstein-Barr virus, Hepatitis B virus and Hepatitis
C virus, and Human papillomavirus (HPV) is the ability to reduce
the expression of cellular E-cadherin. Since E-cadherin is used by
Langerhans cells to move through the stratiﬁed epithelium, its re-
duction may affect the efﬁciency by which the immune system re-
sponds to HPVinfection and the lengthof persistent HPVinfections.
We observed that the E7 protein of this virus (HPV16) is most
efﬁcient at reducing E-cadherin levels. This E7 activity is indepen-
dent of retinoblastoma protein or AP-2a degradation. Instead it is
associated with augmentation of cellular DNA methyltransferase I
(Dnmt1) activity. Signiﬁcantly, inhibition of Dnmt activity re-estab-
lished E-cadherin levels of the cells, presenting the possibility that
similar epigenetic intervention clinically may be a way to re-estab-
lish the inﬂux of Langerhans cells into infected epithelium to coun-
teract HPV persistence.
Introduction
Infection of the cervical epithelium by high-risk human papillomavi-
ruses (HPVs) can predispose this tissue to subsequent development of
cancer (1,2). Activities of HPV proteins that can cause this have been
elucidated and they include the degradation of p53 tumour suppressor
protein, expression of the catalytic subunit of telomerase and inacti-
vation or destruction of the retinoblastoma protein (pRb) protein. The
ﬁrst two activities are carried out by the viral E6 protein, whereas
activities against the pRb are elicited by the E7 protein (3–7). While
the potential contribution of E6 and E7 proteins to the development of
cervical cancer is clear, infection by high-risk HPVs do not automat-
ically result in cancers, as these viruses are usually cleared from the
tissue after some time. Failure to clear the virus, however, would
allow HPV to persist in the cervical epithelium and increase the likeli-
hood of the eventual development of cervical cancer (8–11). Clear-
ance of HPV may be elicited in part by the natural differentiation,
migration and exfoliation of infected keratinocytes from the cervical
epithelium. In addition to this, the host’s immune system also has an
important role to play in viral clearance (12,13). Langerhans cells
inﬁltrate and move within the epithelium and participate in detecting,
processing and presenting foreign antigens to other immunocytes of
the host (14,15). Interestingly, numerous independent investigations
have revealed that HPV-infected cervical epithelia possess fewer
Langerhans cells than the uninfected neighbouring tissues, suggesting
that HPV creates a deﬁned zone that is refractive to Langerhans cells
inﬂux within an otherwise healthy epithelium (16–27). Migration of
Langerhans cells is inﬂuenced by cytokines such as tumour necrosis
factor a (28,29), granulocyte-macrophage colony stimulating factor
(30,31) and interleukin-10 (32) and chemokines including RANTES
and MIP3a (33,34), which are produced by keratinocytes (35).
HPV-containing cells were reported to have reduced expression of
granulocyte-macrophage colony stimulating factor (31) and clinical
lesions containing HPVs are reported to have altered levels of various
cytokines which is unfavourable for the activation of the immune
system(36).Inadditiontostimulatorysignals,migration ofLangerhans
cells requires E-cadherin proteins to be present on the membrane of
keratinocytes (21,29,37,38). Hence it is of particular signiﬁcance that
the amount of E-cadherin protein in HPV-infected tissues is signif-
icantly reduced (21,39–49) or its distribution altered (21,39–
42,44,45,48–53).
Using the keratinocyte cell line NIKS, which was derived from
human foreskin (54), we generated cells that harboured replicating
HPV16 episomes that were able to persist in culture (reminiscent of
a persistent infection) (55). Analyses of these cells revealed that the
level of their E-cadherin protein was indeed reduced, as is seen in
naturally infected cells of the cervical epithelium. However, cells
that harboured HPV16 DNA mutant episomes, which do not express
E7 protein (as a result of a stop codon within the E7 region) did not
exhibit any signiﬁcant reduction in the E-cadherin protein levels,
demonstrating that it is the E7 protein that is predominantly respon-
sible for this. The E7 protein does not target E-cadherin proteins for
proteolytic degradation, anditsabilityto degrade pRbandAP-2a are
not associated with E-cadherin reduction. Instead, the E7 protein
augments the amount and activity of Dnmt1 in the cell, and this in
turn causes a reduction in the transcription of the E-cadherin gene.
These observations uncover yet another activity of HPV16 E7,
which in this instance is one that works at the epigenetic level to
contribute to the successful persistence of HPV in the infected epi-
thelium. Importantly, inhibition of Dnmt activity re-established the
level of E-cadherin expression of the host cell, suggesting that such
epigenetic intervention to recover E-cadherin expression may en-
courage re-inﬁltration of Langerhans cells back into HPV-infected
regions of the epithelium.
Materials and methods
Cell culture
NIKS cells provided by Dr Paul Lambert were cultured in F-medium (three
parts F-12 Ham:1 part Dulbecco’s modiﬁed Eagle’s medium, 5% foetal calf
serum, 24 lg/ml Adenine, 8.4 ng/ml cholera toxin, 5 lg/ml insulin, 0.4 lg/ml
hydrocortison and 10 ng/ml epidermal growth factor). 3T3 cells were cultured
in Dulbecco’s modiﬁed Eagle’s medium supplemented with 10% foetal calf
serum. Brieﬂy, NIKS were grown in 10 cm plates containing 2 million gamma-
irradiated J2-3T3 cells. To generate NIKS cells harbouring episomal HPV16
DNA, NIKS cells plated the day before at 0.5 million in a well of a six-well
platewere transfected with 0.8 lg of recircularized HPV16 DNA and 0.2 lgo f
pCDNA6A (Invitrogen, Carlsbad, CA). The next day, the transfectants were
passed into 10 cm plates with 2 million irradiated blasticidin-resistant J2-3T3.
After attachment of cells on the plate, blasticidinwas added into the medium to
a ﬁnal concentration of 8 lg/ml. Antibiotics selection was stopped when all the
untransfected cells in the control plate were dead.
Plasmids, recircularization of HPV16 DNA and in vitro mutagenesis
The pSPW12 plasmid, from which recircularized HPV16 DNAwas generated,
was provided by Dr Margaret Stanley. Five micrograms of pSPW12 was
digested with BamHI to release the full-length HPV16 DNA, followed by
a ligation reaction with 2000 U of New England Biolab’s T4DNA Ligase in
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recircularized DNA was puriﬁed and concentrated using the QIAGEN mini-
prep kit according to the protocol provided. Mutagenesis to generate HPV16
DNA that cannot express the E7 protein was carried out using the Pfu Ultra
polymerase (Stratagene, La Jolla, CA) according to the protocol provided by
the manufacturer. The mutagenesis primers used were forward primer acattg-
catgaatattagttagatttgcaacc and reverse primer ggttgcaaatctaactaatattcatgcaatgt
were used to introduce a stop codon at nucleotide position 595 of the HPV16
genome. The whole mutant viral DNAwas sequenced to verify the integrity of
the entire HPV16 sequence.
Retrovirus production
Retrovirus vectors (LXSN, LXSN16E6, LXSN16E7 and LXSN16E6/7) were
kindly provided by Dr Denise Galloway. To produce retroviruses, these vectors
were transfected into Phoenix A cells (kindly provided by Dr Nolan), and the
medium of the cells harvested 48 h later and ﬁltered through 0.2 l ﬁlters.
Aliquots were prepared and stored in  80C until use. For infection, viruses
were mixed with polybrene at a concentration of 10 lg/ml and layered onto
thecellmonolayer.Neomycinwasusedat500lg/mlconcentrationforselection.
DNA extraction and Southern blotting
DNA from cells was extracted using the QIAamp kit from QIAGEN (Valencia,
CA) according to the protocol provided by the manufacturer. The eluted DNA
was separated on a 1% agarose gel and blot transferred to nylon ﬁlter and
probed with 32P-labelled HPV16 DNA probe. After hybridization, the ﬁlter
waswashedandexposedtoX-rayﬁlmora phosphorimagerscreenandanalysed.
RNA extraction, reverse transcription and quantitative polymerase chain
reaction
J2-3T3 feeder cells were dislodged from the plate by forceful squirting with
phosphate-buffered saline (PBS). Keratinocytes were trypsinized and the cell
pellet treated according to the protocol supplied by the RNeasy kit from QIAGEN.
The quantity of the resulting nucleic acids were measured and 4 lgw e r et r a n s -
ferred into a tube for DNaseI digestion according to the protocol supplied with the
Ambion DNase away kit, The resulting RNA were reverse transcribed with
Superscript polymerase (Invitrogen) and subjected to quantitative polymerase
chain reaction (PCR) analyses using primers to the E-cadherin complementary
DNA (forward GGTTATTCCTCCCATCAGCT and reverse CTTGGCTGAG-
GATGGTGTA)andbeta-actincomplementary DNA(forward TGGGCATGGGT-
CAGAAGGAT and reverse CGGCCAGAGGCGTACAGGGA).
Protein extraction and western blotting
Prior to harvesting NIKS cells for proteins, the irradiated J2-3T3 cells on the plate
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inverted microscopy, the remaining NIKS cells were scraped off the plate into
a 1.5 ml vial and centrifuged at 6000 r.p.m. (4C) on a bench top microcentrifuge
for 2 min. The supernatant was removed and the cell pellet was resuspended in ice-
cold 200 ll of Reporter Lysis Buffer (Promega, Madison, WI) supplemented with
protease inhibitor cocktail (Bio-Rad, Hercules, CA). The resuspended cells were
sonicatedat 30%powerfor10sfromaBransonsonicator.After 15minincubation
on ice, followed by centrifugation at 15 000 r.p.m. at 4C for 20 min, the clariﬁed
celllysatewascollected and protein was assayed by the Bradford method and
stored at  70C. Proteins were separated on 8, 10 or 15% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis, transferred onto polyvinylidene
diﬂuoride membrane, blocked in 5% milk in PBS–0.5% Tween 20 and
probed with appropriate primary and secondary antibodies.
Dnmt assay
Feedercells wereremovedfrom theplateby squirtingPBSon them.Cells were
then trypsinized, washed once with PBS and resuspended in 1–2 vol of lysis
buffer (50 mM Tris pH 7.8, 1 mM ethylenediaminetetraacetic acid, 20 mM
beta-mercaptoethanol, 10% glycerol, 1% Tween 80 and 60 lg/ml phenylme-
thylsulfonyl ﬂuoride) followed by three rounds of freeze-thawing and sonica-
tion at 35% intensity for 10 s. After centrifugation at 13 000 r.p.m. in
a microcentrifuge at 4C, the clariﬁed cell lysate was collected and the protein
concentration measured by the Bradford method. Five micrograms of protein
lysate was used in the assay which contained 0.5 lg poly(dI-dC) and 3 lCi of
S-adenosyl-L-[methyl-3H] methionine in a ﬁnal volume of 20 ll. The mixture
was incubated for 2 h at 37C, after which the reaction was stopped by placing
the tubes in ice water. Two microlitres of 5 mg/ml Herring sperm DNA was
addedand thewholemixturesubjectedto puriﬁcationwithQIAGENmini-prep
kit according to the protocol provided. DNA was eluted in 50 ll of elution
buffer, followedby ethanol precipitation of the DNA. The resultingDNA pellet
was washed twice with 1 ml 70% ethanol and ﬁnally resuspended in 20 llo f
water and spotted onto GF/C ﬁlter. After addition of 10 ml of scintillation ﬂuid,
the samples were counted in a scintillation counter.
Bisulphite conversion and sequencing of the E-cadherin promoter region
DNA from cells was extracted using QIAmp kit from QIAGEN according to
the protocol provided by the manufacturer. Five hundred nanograms of DNA
was bisulphite converted using EZ DNA Methylation-Gold Kit from Zymo
Research (Orange, CA). DNAwas mixed with CT conversion reagent contain-
ing sodium hydroxide for DNA denaturation and sodium bisulphite for sulpho-
nation of C6 of the pyrimidine ring. Reaction was carried out in a thermal
cycler at 98C for 10 min, followed by 64C for 2.5 h. The converted samples
were loaded into the provided columns that were prepared with M-binding
buffer containing guanidine hydrochloride to act as a chaotropic reagent.
The column was washed with M-Wash buffer and then incubated with
M-Desulphonation Buffer (containing sodium hydroxide to provide hydroxide
ions for removal of the sulphite group from the pyrimidine ring) for 15 min at
room temperature. The column was then washed another two times and DNA
was eluted in 10 ll and stored at  70C. Seventy-ﬁve nanograms of DNAwas
used for the ﬁrst PCR with the following primers whose sequences were based
on the E-cadherin promoter sequence in Genebank with the accession number
of L34545. The positions of these primer sequences were based on those
reported by Reinhold et al. (56). Some modiﬁcations were introduced to the
reported sequences in order to minimize difference in the annealing temper-
atures between the primers: forward primer, TTGATTTTAGGTTTTAGT-
GAGTT (sequence position  399 to  377) and reverse primer,
AACTCCAAAAACCCATAACTAA (sequence position  6t oþ16). These
primers were used to amplify a fragment of 415 bp. The PCR cycles were
94C for 2 min followed by 35 cycles of 94C for 1 min, 55C 1 min and 72C
for 1 min and ended with 72C for 2 min. One microlitre of the ﬁrst PCR was
then removed and used for nested PCR using the following primers: forward
nested primer, GTAAAACGACGGCCAGTTATTTAGATTTTAGTAATTTT
(sequence position  319 to  299) and reverse nested primer, GGAAACAGC-
TATGACCATGAACTCCAAAAACCCATAACTAA, which annealed to the 3’
terminus of the ﬁrst PCR product. The resulting nested PCR product contains
all 25 CpGs in the minimal E-cadherin promoter region (56) and an additional
four CpGs in the 3#end. The PCR product was separated on a 1% agarose gel
and the expected DNA fragment of  335 bp was excised from the gel and
puriﬁed using QIAquick Gel Extraction kit from QIAGEN according to the
protocol provided by the manufacturer. The PCR product was then ligated into
the pGEM-T Easy vector system from Promega and transformed into XL1-
Blue Supercompetent Cells from Stratagene. The cells were then plated onto
agar containing ampicillin and X-gal overnight and single white colonies were
picked for culture in Luria–Bertani broth containing ampicillin. QIAprep Spin
Miniprep kit from QIAGEN was used to isolate the plasmid DNA. The DNA
preparations were digested with EcoRI to release the cloned PCR fragment and
separated on an agarose gel to verify fragment size. Individual plasmid clones
obtained from NIKS and NIKS þ HPV16 were sent to Geneservice for se-
quencing using T7 primers. Secondary structure protocol sequencing was re-
quired in order to obtain complete sequences of the samples. The sequences
were aligned using SeqMan software and all cytosines were analyzed for
conversion status. Assuming that CpA, CpC and CpT (collectively referred
to here as CpN) are not methylated, they are expected to be converted by the
bisulphite reaction. As such, efﬁciency of the conversion reaction can be as-
certained by dividingthe numberof converted CpN by the total number of CpN
within the sequence, and this gave conversion rates of 98.8% for NIKS and
99.3% for NIKS þ HPV16 sequences. Furthermore, we ascertained that un-
converted DNA (not put through the bisulphite reaction) could not be ampliﬁed
with the primers used above. Conversely, primers designed to amplify un-
converted DNA from the exact region of the E-cadherin promoter above
cannot amplify bisulphite converted DNA (data not shown). The efﬁciency
and completeness of the bisulphite conversion reaction is demonstrated by
the fact that DNA sequencing of the converted and cloned PCR fragments
revealed that virtually all (98.8 and 99.3%) the cytosines of CpNs were
converted to thymines in the individual clones. To control for the absence
of over-conversion, we methylated the CpGs of the DNA in vitro with SssI
methyltransferase and then subjected it to bisulphite conversion in parallel
with the test reactions and the protocol described above. Sequencing of
these DNA revealed that while the cytosines of CpN were converted,
those of CpGs were not (data not shown). Collectively, these controls dem-
onstrate that the bisulphite conversion was efﬁcient and speciﬁc (with no
over-conversion).
Results
Persistence of HPV16wt episomes and HPV16E7-null episomes in
NIKS cells
In order to generate an in vitro culture system to study long term HPV
persistence, NIKS cells, which were derived from foreskin
Papillomavirus, E7 protein, Dnmt1 and E-cadherin
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HPV DNA replication (54,55). HPV16 DNAs excised from plasmids
were recircularized and co-transfected into these cells with pcDNA6
plasmids, which express blasticidin-resistance protein. Following anti-
biotics selection, cells were passaged at least 10 times and at each
passage, DNAs were extracted from an aliquot of cells for analyses
by Southernblotting.AsshowninFigure1aHPV16episomespersisted
in these cells without any apparent loss or gross reduction of copy
number through all the passages. In parallel, recircularized HPV16
genomes with a stop codon inserted in either the E6 or E7 open reading
framewerealsoputthroughthe processdescribedabove.While theE6-
nullHPVgenomefailedtopersist(datanotshown),theE7-nullHPV16
genome readily persisted in these cells (Figure 1b). The unexplained
requirement for E6 in HPV16 persistence is consistent with similar
observations in several previous reports (57,58). These lines of cells
allowed us to address, in vitro, the above-mentioned phenomenon of
reduction of E-cadherin levels in HPV-containing epithelial lesions.
Differences in E-cadherin protein levels in NIKS, NIKS HPV16wt and
NIKS HPV16E7null cells
When protein lysates from NIKS cells and those that harboured wild-
type HPV16 episomes were analyzed, it was apparent that the level of
E-cadherin was signiﬁcantly reduced in the latter, whether they were
in a state of conﬂuence or not (Figure 2a). This is reminiscent of HPV-
containing cervical lesions, which were reported to have reduced
expression of E-cadherin (21,39,42,44,45,48,49). However, when ex-
tracts from two independently generated lines of NIKS cells bearing
HPV16E7-null episomes were tested, no appreciable reduction of the
E-cadherin levels was apparent (Figure 2b). Detection of E7 protein
exclusively in cells harbouring the wild-type HPV genomes attests to
the fact that the E7-null mutant genomes were truly not expressing E7
proteins. The reduced levels of p53 protein in cells bearing wild-type
or E7-null viral DNA is indicative of E6 expression, as HPV16 E6 is
able to target p53 protein for proteasome-mediated degradation.
These analyses conﬁrmed that wild-type HPV16 DNA expressed
both, the E6 and E7 proteins, whereas the HPV16 E7-null episomes
expressedonlythe E6 protein. Assuch, these results showthat HPV16
E7 protein was responsible for the reduction of E-cadherin levels in
cells that harboured HPV16 episomes.
Fig. 1. Southern blot analyses of DNA extracted from various passages
(p) of (a) NIKS cells that harbour wild-type HPV16 DNA and (b) NIKS cells
that harbour E7null HPV16 episomes. The blots were probed with full-length
HPV16 DNA. The size marker used was a 1 kb supercoiled DNA ladder.
Fig. 2. (a) Western blot of proteins extracted from NIKS and NIKS-bearing
episomal HPV16 DNA. Lysates were prepared from either conﬂuent or
subconﬂuent cells. The membrane was probed with antibodies against
E-cadherin or actin. (b) Lysates of NIKS cell, NIKS carrying wild-type
episomal HPV16 DNA and two independently derived NIKS lines
harbouring E7null HPV16 episomes were analysed by western blotting using
antibodies against HPV16 E7, p53, E-cadherin and actin. Two independent
analyses of E-cadherin of these cells are shown. (c) Western blots of protein
lysates from NIKS cells that were infected with LXSN retrovirus (vector),
LXSN E6, LXSN E7 or LXSN E6/7, after selection with neomycin.
Antibodies against E-cadherin, p53 and actin were used.
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920HPV16 E7 alone is responsible for the reduction of E-cadherin
protein level in cells
While the evidence is sufﬁciently compelling to suggest that the E7
protein is responsible for the reduction of E-cadherin protein level, it
does not exclude the possibility that the E6 protein might also be
required for this activity. This possibility is particularly pertinent in
view of a report that demonstrated HPV16 E6 to reduce E-cadherin
levels (41). In this light, it is conceivable that E6 and E7 proteins may
act together to bring about this effect. To test this, NIKS cells were
infected with retroviruses bearing E6, E7 or E6 plus E7 (E6/7) genes.
Infected cells were selected with neomycin and the surviving infec-
tants were harvested and their E-cadherin proteins analyzed
(Figure 2c). The E-cadherin level in E6-expressing cells was compa-
rable with that of control cells. However, E7 and E6/7 infectants
exhibited markedly reduced levels of E-cadherin protein. Consistent
with what has been reported regarding the effects of E6 and E7 pro-
teins on p53; the p53 protein level in E6-expressing cells was reduced
(5), whereas that in E7-expressing cells was increased (59). These
results show that HPV16 E7 alone is able to reduce E-cadherin protein
levels, and the absence or presence of E6 has no perceivable impact on
this activity. It must be noted that in the multiple repeats of these
experiments, there were occasions when the E6 protein alone was
seen to slightly reduce E-cadherin protein level. However, unlike
E7-induced reduction of E-cadherin, the E6-induced reduction is
modest and curiouslyinconsistent. This erratic effectof E6 is apparent
in some results in the following sections below.
HPV16 E7 protein does not target E-cadherin protein fordegradation
To ascertain how HPV16 reduces E-cadherin level, we ﬁrst tested
the possibility that E-cadherin may be targeted for proteasomal
degradation. Cells were either mock treated or treated with protea-
some inhibitor ALLN, and the proteins from these cells were analyzed
by western blotting (Figure 3a). While the E-cadherin protein levels in
NIKS cells were augmented upon proteasome inhibition, E-cadherin
protein level in cells that harboured HPV16 DNA was not altered.
That the proteasome was indeed inhibited was attested by the fact
that ALLN treatment increased the p53 protein levels in all the cells as
p53’s degradation is proteasome mediated. This result suggests that
HPV16 does not reduce E-cadherin levels in cells by channelling
E-cadherin protein for degradation by proteasome.
HPV16 E7 suppresses transcription of E-cadherin gene
We set out to test the alternative possibility that HPV16 may repress
the expression of the E-cadherin gene instead. RNA isolated from
NIKS cells, NIKS bearing HPV16DNA and NIKS cells infected either
with control or E7 retroviral vectors were reverse transcribed and the
complementary DNA of E-cadherin and that of beta-actin were mea-
sured using quantitative PCR. The results in Figure 3b show that the
amount of E-cadherin transcripts (normalized against beta-actin tran-
scripts) in cells harbouring HPV16 episomes or expressing E7 was
markedly reduced. Although this result does not exclude the possible
involvement of non-proteasomal degradation of E-cadherin, it never-
theless demonstrates that repression of gene expression is a means by
which HPV16 reduces E-cadherin levels in the cell.
Reduction of E-cadherin protein level by HPV16 E7 is independent of
pRb degradation or AP-2a downregulation
The best-characterized activity of HPV16 E7 is pRb degradation. As
pRb protein has a profound effect on the expression of many cellular
genes, it is possible that E7’s repressive effect on E-cadherin expres-
sion is mediated via pRb degradation. Indeed, a recent report alluded
to the possibility that degradation of pRb and AP-2a is responsible for
repressing E-cadherin expression (60). Immunoblotting with antibod-
ies against pRb and AP-2a revealed that while pRb level was clearly
reduced in HPV16-containing cells, the level of AP-2a protein re-
mained unchanged between NIKS and NIKS þ HPV16wt, in spite
of a very clear reduction of E-cadherin level in the latter cells
(Figure 4a). This observation excludes AP-2a degradation as a means
by which E7 represses E-cadherin expression in our experimental
system. To test whether pRb degradation by itself could reduce
E-cadherin levels, we infected NIKS cells with recombinant retrovi-
ruses expressing short hairpin RNA against pRb. From Figure 4b, it is
clear that although short hairpin RNA against pRb reduced the pRb
protein level markedly, the level of E-cadherin was unchanged,
indicating that degradation of pRb is not the means by which E7
represses E-cadherin expression.
HPV16 E7 augments the level of Dnmt1 in cells
In considering how E-cadherin expression can be suppressed by HPV
E7, it is of particular interest to note how other viruses affect similar
repression on the expression of this gene. In particular, the hepatitis B
virus (HBV) also reduces E-cadherin expression in cells (61–63). This
is achieved by the HBV X protein, which augments the level and
activity of Dnmt1, which goes on to repress E-cadherin expression.
As such we considered the possibility that the HPV16 E7 may also do
likewise. Analyses of the Dnmt1 protein of NIKS cells and those that
harbour HPV16 episomes revealed that HPV16 does indeed augment
greatly the level of Dnmt1 (Figure 4c). Dnmt3a level was also
Fig. 3. (a) Analyses of E-cadherin protein in NIKS and NIKS harbouring
wild-type HPV16 episomes, with (þ) and without ( ) treatment with the
proteasome inhibitor, ALLN. Actin served as loading control and p53 served
to indicate that the proteasome was indeed inhibited by the compound.
(b) Quantitative PCR measurements of E-cadherin transcripts in NIKS (ctrl),
NIKS containing HPV16 episomes (HPV16), NIKS infected with empty
retroviral vector (LXSN) or E7-contaning retroviral vector (LXSNE7).
E-cadherin transcripts are normalized against beta-actin transcript levels.
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were below the level of detection (data not shown). By immunoblot-
ting NIKS cells that were infected with either empty retroviral con-
struct or those bearing the E6 or E7 genes, we observed that the E7
protein increased greatly the protein level of Dnmt1 (Figure 4d). To
test whether the augmented levels of Dnmt1 protein affects Dnmt
activity, we assayed the lysates of these cells and observed that
HPV16 or HPV16E7 protein alone, both increased the activity of
Dnmt in the cells (as shown in Figure 4e).
Inhibition of Dnmt activity allows recovery of E-cadherin levels
Augmentation of Dnmt activity by HPV16 is particularly relevant in the
context of repression of E-cadherin expression. Many cellular pro-
moters, including that of E-cadherin, are silenced when methylated by
Dnmts. Indeed it is through such a mode of repression that E-cadherin
levels are diminishedby HBV (61–63), Hepatitis C virus (HCV) (64,65)
and Epstein-Barr virus (EBV) (66–69). If augmenting Dnmt activity is
relevant to HPV-mediated repression of E-cadherin, then inhibition of
Dnmt would be expected to derepress E-cadherin expression in
cells containing HPV DNA or HPV oncogenes. To test this, 5-aza-
deoxycytidine or DAC, an inhibitor of Dnmt was fed to the cells. This
resulted in the recovery of the E-cadherin protein levels in cells con-
taining HPV16 DNA or expressing E7 protein (Figure 5a). This recov-
ery was also evident at the transcription level when the RNA of Fig. 4. (a) Western blot analyses of E-cadherin, pRb and AP-2a proteins
from NIKS and NIKS þ HPV16wt DNA. (b) Analyses of E-cadherin and
pRb in cells infected with retrovirus-expressing shGFP or retrovirus-
expressing short hairpin RNA against pRb (shpRb). Beta-actin was used as
loading control. (c) Western blot analyses of Dnmt1, Dnmt3a, p53 and actin
in protein extracts of NIKS (Ctrl) and NIKS harbouring episomal HPV16
DNA. (d) Analyses of Dnmt1 protein in extracts from NIKS cells infected
with LXSN (vector), LXSNE6 or LXSNE7 retroviruses, after selection with
neomycin. Actin serves as loading control. (e) DNA methyltransferase assay
of proteins extracted from NIKS cells (Ctrl), NIKS cells harbouring HPV16
episomes, NIKS cells infected with empty retroviral vector (LXSN) or E7-
bearing retroviruses (LXSNE7). Bkg is the background counts of the assay.
Fig. 5. Treatment of NIKS and various NIKS-derived cells with inhibitor of
DNA methyltransferase, 5-aza-deoxycytidine (DAC). (a) Protein lysates
were prepared and analysed on a western blot with antibodies against
E-cadherin and beta-actin (as loading control). (b) RNAs were extracted
from treated (þ) or untreated ( ) cells and E-cadherin and beta-actin
transcripts were extracted and their relative amounts measured using
quantitative PCR and normalized against beta-actin transcripts.
J.Laurson et al.
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or its oncogenes were refractive to 5-aza-deoxycytidine, conﬁrming that
the HPV-induced augmentation of Dnmt activity does indeed cause the
repression of E-cadherin expression. The observations described hith-
erto demonstrate that HPV increases cellular Dnmt activity and this in
turn is responsible for decreasing the E-cadherin gene expression. It
does not, however, mean that Dnmt acts directly on the E-cadherin
promoter. To test this, we subjected DNA from NIKS and NIKS þ
HPV16 to bisulphite reaction which converts cytosines to thymines,
unless the cytosines were methylated. This was followed by PCR clon-
ing and sequencing of the E-cadherin promoter. We observed that NIKS
cells harbouring HPV16 episomes did not exhibit any convincing differ-
ences in the CpG methylation state of their E-cadherin promoters from
those of cells devoid of the virus. In fact the E-cadherin promoters in
these cells (with or without HPV16) were almost fully unmethylated
(Figure 6). This observation means that while HPV-induced augmenta-
tion of Dnmt activity is responsible for repressing E-cadherin gene
expression, this repression is not brought about by methylation of the
E-cadherin promoter. Instead, the results suggest that the E7-increased
Dnmt activity targets a cellular genes whose protein products impinge
on the E-cadherin promoter. One potential candidate is Slug, the re-
pressor of E-cadherin expression (70,71). We tested to see if the protein
level of Slug is altered in these cells. Western blotting revealed that the
level of Slug was comparable in all the cells tested (data not shown),
hence excluding it as the mediator of E-cadherin repression by E7. At
this pointintime,wedonotknowthe Dnmttargetthatisresponsiblefor
the HPV-induced reduction of E-cadherin. This notwithstanding, it is
clear that HPV, like the other cancer-associated viruses (HBV, HCVand
EBV) is able to modulate through epigenetic means, expression of the
cellular E-cadherin gene. While this results in direct methylation of the
E-cadherin promoter by the other viruses, HPV-induced augmentation
of Dnmt activity results in the indirect repression of the E-cadherin
promoter.
Discussion
Observations from numerous independent analyses of clinical sam-
ples have consistently revealed that HPV-containing lesions have
markedly reduced levels of E-cadherin protein. This study and those
of Matthews et al. (41), Caberg et al. (60) and Hellner et al. (72)
collectively show that this is not a secondary feature that is acquired
by the cell independently of HPVaction. Instead HPVdirectly reduces
cellular E-cadherin expression. In the experiments described above,
we show that the E7 protein is capable of reducing E-cadherin levels
independently of any other viral proteins. As such we conclude that
the E7 protein is the major instigator of E-cadherin reduction. How-
ever, it is noteworthy that the E6 protein may also contribute to this
activity in vivo. We are mindful that in the context of the tissue, the
relative expression and contribution of E6 and E7 to reducing
E-cadherin level may be different or synergistic. This notwithstand-
ing, it is clear that the E7 protein is able to do this on its own as
expression of E7 alone or in the context of E6 resulted in comparable
reduction of E-cadherin. While it would have been ideal to generate
a NIKS line that harbour HPV16E6null DNA, we and others have not
been able to generate such a cell line beyond the second passage
(highlighting the requirement of E6 for HPV persistence in replicating
cells) (57,58). Hence recombinant retroviruses were used to address
this question instead. Although we can be conﬁdent that reduction of
E-cadherin is not brought about via degradation by the proteasome
system, we cannot exclude the possibility that E-cadherin could be
channelled by E7 for degradation via another cellular proteolytic
system. What is clear, however, is that E7 does reduce the expression
of E-cadherin at the transcription level as the quantity of E-cadherin
RNA was clearly reduced in cells with HPV16 DNA or HPV16E7
protein. The report by Caberg et al. (60) suggests that E7 does this by
the combined reduction of pRb and AP-2a. From the outset, this did
not appear to be case in our cells as while pRb was reduced by E7, the
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Fig. 6. Methylation status of CpGs within the E-cadherin promoter. The methylation state of each CpG within the E-cadherin promoter (position  319 to þ16)
was analyzed and obtained from nucleotide sequences of 17 individual clones each of bisulphite-converted DNA that were isolated from NIKS cells and
NIKS cells harbouring HPV16DNA.
Papillomavirus, E7 protein, Dnmt1 and E-cadherin
923level of AP-2a was not. This is consistent with a previous report that
showed that although reduction of AP-2a can occur, as it does in SiHa
cells used by Caberg et al., it is actually a rare event in cervical cancers
(73). Furthermore, knock down of pRb levels using shRNA did not
reduce E-cadherin levels. Our attention was turned to the interesting
fact that several other cancer-associated viruses (HBV, HCVand EBV)
also reduce E-cadherin level by reducing expression of this gene. They
all did this by repressing the E-cadherin promoter. HBV, via its
X protein, activates Dnmt1 expression and causes the repression of
E-cadherin expression (61–63). Likewise, EBV latent membrane pro-
tein 1 protein activates Dnmt1 expressionvia C-Jun-N-terminal kinase-
Activator protein 1 pathway and asa consequence represses E-cadherin
expression (66–69). HCV core protein represses E-cadherin also by
activating Dnmt1 and Dnmt3b (64,65). It is very likely that these
viruses (including HPV) derive the common advantage of immune
evasion by this method. Interestingly all these viruses (HBV, HCV
and EBV) including HPV16 repress E-cadherin expression via activa-
tion of Dnmt1. For HPV16, this was brought about by E7-mediated
augmentation of Dnmt1 protein and activity. This characteristic of E7
wasalsoobservedbyBurgersetal.(74),whoshowedthatE7associates
directly and physically with the Dnmt1 protein. This association con-
tributes to the stability of the Dnmt1 protein (74). Mutation of pRb-
interactionregionoftheE7proteindid notobliteratetheabilityofE7to
activate Dnmt activity, demonstrating that E7 increases the levels and
activity of Dnmt primarily by direct association with the protein (74)
andindependentlyofpRbdegradationasobservedbyus.The relevance
of Dnmt1 increase and activation in regards to E-cadherin repression
was made clear when inhibition of Dnmt by 5-aza-deoxycytidine re-
established RNA and protein levels of E-cadherin in cells containing
HPV16DNAorexpressingHPVproteinsbutnotincontrolcellsthatdo
not contain HPV DNA.
Up to this point, the mechanism by which HPV16 repressed
E-cadherin appears to parallel those of HBV, HCV and EBV. How-
ever, while the other viruses instigated a Dnmt1-mediated methyla-
tion of the E-cadherin promoter, neither HPV16 nor E7 protein
appeared to do this. Instead the promoter of E-cadherin remained
largely unmethylated whether or not HPV was present. This suggests
that E7-augmented Dnmt1 activity is targeted to a cellular gene/genes
whose protein acts on the E-cadherin promoter. Testing revealed that
although the protein Slug was a prime candidate to be such a mediator
(71,75,76), neither its level nor localization was altered by E7. As yet
we have not identiﬁed what the cellular factors are. The difference
between HPV and the other cancer-associated viruses is interesting
when we consider that while cancers (hepatocellular carcinomas and
lymphomas) that are associated with the other viruses (HBV, HCVand
EBV) usually have their p16 promoter repressed by DNA methylation
(presumably owed to virus-mediated increase of Dnmt activity), cer-
vical lesions containing HPV do not have their p16 promoters meth-
ylated. This stark difference suggests that while the other viruses
increase Dnmt activity more generally, HPV does not. How this ﬁne
control is elicited by HPVis not known but it may be linked to the fact
that not only does E7 increase Dnmt1 activity, but it also binds to the
Dnmt1 protein (74). It is possible that this interaction allows E7 to
target Dnmt1 to speciﬁc sites as opposed to allowing Dnmt1 to act
more liberally. Interestingly a precedent for this, from yet another
virus, was presented by Shamay et al. (77) who reported that the
LANA protein of the Kaposi’s sarcoma-associated herpes virus phys-
ically associates with Dnmt3a and recruits the latter to speciﬁc sites
on the cellular DNA to affect gene expression. This site-speciﬁc
epigenetic modiﬁcation may be the way by which HPV can modulate
expression of some cellular genes without causing a general change in
the epigenetic state of the host genome. The testing of this hypothesis
should prove interesting as it may reveal further activities of E7 and
uncover pathways that regulate E-cadherin expression that are cur-
rently unknown.
In summary, our observations outlined above demonstrate that the
HPV16 E7is capableofreducing the levelsofE-cadherin inthecellvia
a mechanism that is partially similar to that employed by other human
cancer-associated viruses (e.g. HBV, EBV and HCV). Mechanism
aside, the reduction of E-cadherin itself is of signiﬁcant importance.
Work from Hellner et al. (72) suggests that the reduction of E-cadherin
is a consequence of HPV16E7-mediated epithelial-mesenchymal tran-
sition, although HPV16 E6 and E7 have been reported by Azzimonti
et al. (78) to prevent epithelial-mesenchymal transition instead. What-
ever the casemay be, it does not detract from the fact that reduced level
of E-cadherin on the cell surface will reduce the efﬁciency of immune
surveillanceoftheepithelium.Thispointissupportedbyarecentreport
byHubertetal.(21),whichshowed that ectopicexpressionofE-cadherin
induced migration of Langerhans cells into stratiﬁed layers of SiHa
(HPV16 containing) cells in an organotypic culture. As such the
reduction of E-cadherin levels in cervical lesions (21,39–
42,44,45,48–53) may be one of the biggest contributors to the depletion
of Langerhans cell number in HPV-infected epithelium, as reported by
numerous investigators (16–27,79). In the case of HPV-infected epithe-
lia, the reduced ability of Langerhans cells to inﬁltrate into virus-
infected area of the tissue would aid the persistence of the virus in
the host. Such persistence is thought to be the prelude to the eventual
development of cervical cancer. The observed recovery of E-cadherin
levels upon inhibition of Dnmt activity provides some optimism to
the notion that such epigenetic targeting may be effective in clearing
persistence of HPV in the infected tissue.
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